DiscoverThe Lancet Regional Health Americas in conversation withBeatriz Grinsztejn on Lenacapavir and the future of HIV prevention
Beatriz Grinsztejn on Lenacapavir and the future of HIV prevention

Beatriz Grinsztejn on Lenacapavir and the future of HIV prevention

Update: 2025-07-21
Share

Description

In this episode, our editor-in-chief Taissa Vila sits down with Dr. Beatriz Grinsztejn to discuss the challenges of expanding access to pre-exposure prophylaxis (PrEP), with a focus on issues of adherence and equity in Latin America. 

We explore the potential of Lenacapavir as a game-changing intervention, reflect on lessons learned from previous experiences with injectable PrEP, and examine the critical importance of introducing new prevention tools through an equity-based approach. 

Finally, we look ahead to what Lenacapavir could mean for the future of HIV prevention strategies worldwide. Tune in for an insightful conversation on how innovative strategies like Lenacapavir could reshape the future of HIV awareness and prevention.

Read the full article:

https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00156-5/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laname

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Beatriz Grinsztejn on Lenacapavir and the future of HIV prevention

Beatriz Grinsztejn on Lenacapavir and the future of HIV prevention

Lancet